Aura Biosciences, Inc. (AURA) Stock Analysis & Investment Frameworks
Aura Biosciences, Inc. (AURA) stock analysis on Invetso. Review Aura Biosciences, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Aura Biosciences, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Aura Biosciences, Inc. Key Financial Metrics
- Market Cap: $669.93M
- Revenue: $N/A
- ROE: -73.18%
- ROIC: -41.61%
- Dividend Yield: N/A
About Aura Biosciences, Inc.
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Aura Biosciences, Inc. Investment Frameworks
Invetso analyzes Aura Biosciences, Inc. (AURA) across the following frameworks:
- Aura Biosciences, Inc. 10Y Growth Potential
- Aura Biosciences, Inc. Scenario Analysis
- Aura Biosciences, Inc. Risks & Opportunities
- Aura Biosciences, Inc. Economic Moat
- Aura Biosciences, Inc. Business Model
- Aura Biosciences, Inc. Management
- Aura Biosciences, Inc. SWOT Analysis
- Aura Biosciences, Inc. Porter's 5 Forces
- Aura Biosciences, Inc. PESTLE Analysis
- Aura Biosciences, Inc. ESG Analysis